arrow_back Back to App

Study on Pharmacy Benefit Managers to Lower Drug Costs.

This act aims to investigate how Pharmacy Benefit Managers (PBMs) influence drug prices. The goal is to understand their role in the supply chain, competition among them, and their use of rebates and fees. The study's findings are intended to help develop policies that will lower drug costs for patients and improve market transparency.
Key points
The act requires the Government Accountability Office (GAO) to conduct a detailed study of Pharmacy Benefit Managers (PBMs).
The study will assess whether PBMs favor higher-rebate, more expensive drugs over lower-cost alternatives.
The report must include data on how much of the rebates PBMs pass on to patients and payers, and how much they keep.
The objective is to provide legislative recommendations to lower prescription drug costs for consumers and enhance market competition.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_1829
Sponsor: Rep. Harshbarger, Diana [R-TN-1]
Process start date: 2021-03-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmacy Benefit Manager Accountability Study Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_1829.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-11.

What are the main provisions?

Key points include:

  • The act requires the Government Accountability Office (GAO) to conduct a detailed study of Pharmacy Benefit Managers (PBMs).
  • The study will assess whether PBMs favor higher-rebate, more expensive drugs over lower-cost alternatives.
  • The report must include data on how much of the rebates PBMs pass on to patients and payers, and how much they keep.
  • The objective is to provide legislative recommendations to lower prescription drug costs for consumers and enhance market competition.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Harshbarger, Diana [R-TN-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Economy